Ro-053061

Ro-053061

SCHEMBL2615409

O=C1CN=C(c2ccccc2)c2cc(F)ccc2N1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 2/20 0.71
CNR1 P21554 1/20 0.71
NTSR1 P30989 1/20 0.71
OPRK1 P41145 1/20 0.71
GABRA1 P14867 5/20 0.69
GABRA5 P31644 5/20 0.69
GABRA3 P34903 5/20 0.69
GABRA2 P47869 5/20 0.69
GABRB2 P47870 4/20 0.69
GABRG2 P18507 3/20 0.69
GABRB3 P28472 3/20 0.69
LMNA P02545 2/20 0.65
HPGD P15428 1/20 0.65
KMT2A Q03164 1/20 0.59
JAK2 O60674 1/20 0.53
RET P07949 1/20 0.53
MAP2K1 Q02750 1/20 0.53
MAP4K2 Q12851 1/20 0.53
GABRP O00591 1/20 0.52
GABRD O14764 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ro-053061 SCHEMBL2615407 1.00 PDE4D (0.71) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL2631571 0.92 GABRA1 (0.64) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL2615410 0.86 GABRA1 (0.59) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL2615406 0.86 GABRA1 (0.59) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL13538415 0.83 PDE4D (0.71) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL1421181 0.83 KMT2A (0.82) PDE4DCNR1NTSR1OPRK1GABRA1
Nordazepam SCHEMBL78453 0.83 PDE4D (1.00) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL7331808 0.83 CHRM1 (0.71) PDE4DCNR1NTSR1OPRK1GABRA1
SCHEMBL11821347 0.83 CHRM1 (0.71) PDE4DCNR1NTSR1OPRK1GABRA1
7-Amino-Nitrazepam SCHEMBL15435607 0.83 PDE4D (0.71) PDE4DCNR1NTSR1OPRK1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2012-04-19 US disclosed
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2012-04-19 US disclosed
WO-2010081036-A2 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095217-A1 FLUORINE CONTAINING COMPOUNDS AND METHODS OF USE THEREOF FLI1, CDC73, FOS PDE4D 2329/4885CNR1 3476/4885NTSR1 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.